Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–9 of 9 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
Recruiting
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT07471841
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, IDH1 Mutation, +6 more
- Locations
-
- Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States
Recruiting
Ivosidenib as Post-HSCT Maintenance for AML
NCT06707493
- Conditions
- Acute Myeloid Leukemia (AML), Hematologic Diseases, Hematopoietic Stem Cell Transplant (HSCT), +7 more
- Locations
-
- Emory University Hospital Atlanta, Georgia, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Ohio State University Wexner Medical Center- James Cancer Hospital Columbus, Ohio, United States
NCT06161974
- Conditions
- Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, +36 more
- Locations
-
- Children's Hospital Colorado Aurora, Colorado, United States
- Children's National Medical Center Washington D.C., District of Columbia, United States
- University of Miami Hospital and Clinics Miami, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839
- Conditions
- AML, IDH1 Mutation, Treatment
- Locations
-
- Blood Diseases Hospital Tianjin, Tianjin Municipality, China
NCT06782542
- Conditions
- Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
- Locations
-
- University of Miami Miami, Florida, United States
Not Yet Recruiting
Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
NCT07664839
- Conditions
- Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
- Locations
-
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
NCT04056910
- Conditions
- Advanced Solid Tumor, Glioma, IDH1 Mutation, +7 more
- Locations
-
- UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
Completed
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
NCT03914742
- Conditions
- Astrocytoma, Glioblastoma, Glioma, +12 more
- Locations
-
- UAB Comprehensive Cancer Center Birmingham, Alabama, United States
- University of California, Los Angeles Los Angeles, California, United States
- Yale University New Haven, Connecticut, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
Active, Not Recruiting
Niraparib In Recurrent IDH 1/2 Gliomas
NCT05406700
- Conditions
- Glioma, Glioma, Malignant, IDH1 Mutation, +10 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States